Opiant Pharmaceuticals, INC. Stock: price and insider trades · United States · SEC (Form 4)

About Opiant Pharmaceuticals, INC.

Opiant Pharmaceuticals, Inc. (ticker OPNT) was a U.S.-listed biopharmaceutical company that traded on NASDAQ in the United States. Headquartered in Santa Monica, California, Opiant focused on therapies for addiction and drug overdose, positioning itself in a highly specialized and socially important corner of the pharmaceutical market. In its SEC filings, the company described itself as a specialty pharmaceutical company developing medicines for addiction and overdose, with an emphasis on intranasal and other rapid-delivery technologies. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1385508/000138550822000121/opnt-20220630.htm?utm_source=openai)) The company’s best-known historical asset was NARCAN® (naloxone hydrochloride) Nasal Spray, a product conceived and developed by Opiant before being licensed to Adapt Pharma. According to SEC disclosures, NARCAN was approved by the FDA in November 2015 and later became a major reference product in the overdose-reversal category. That history gave Opiant strong scientific credibility and established the company as an important innovator in opioid overdose reversal, a market shaped by public-health urgency and regulatory attention. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1385508/000138550822000121/opnt-20220630.htm?utm_source=openai)) Opiant’s pipeline extended beyond a single product. Its SEC disclosures show development programs in opioid overdose reversal, alcohol use disorder, and acute cannabinoid overdose, with OPNT003 highlighted as a key follow-on candidate. The company also pursued a 505(b)(2) regulatory pathway for OPNT003, underscoring a strategy built around reformulation, differentiated delivery, and potentially accelerated clinical/regulatory development. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1385508/000138550822000038/opnt-20211231.htm?utm_source=openai)) From a competitive standpoint, Opiant was a niche specialist rather than a broad diversified drugmaker. Its competitive edge came from focused expertise in addiction medicine, nasal drug-delivery innovation, and the ability to address urgent overdose intervention needs. That made the company relevant not only to investors seeking exposure to specialty pharma, but also to the broader public-health ecosystem around the U.S. opioid crisis. The company’s commercial relevance was therefore tied to a narrow but high-impact therapeutic area, where brand recognition and clinical utility matter more than scale. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1385508/000138550822000121/opnt-20220630.htm?utm_source=openai)) Geographically, Opiant’s core operations were based in California, with Santa Monica as its corporate home and a business footprint centered in the United States. The most important recent corporate event was its acquisition by Indivior: the transaction was announced in November 2022 and completed on March 2, 2023. As a result, OPNT is no longer an independent listed company, which is important context for investors reviewing legacy SEC Form 4 insider transaction data. In practical terms, OPNT should now be viewed as a historical NASDAQ-listed issuer that was absorbed into Indivior’s broader addiction-treatment platform. ([opiant.com](https://www.opiant.com/en/media/press-releases/INDV-OPNT-111422?utm_source=openai))